Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life

Voruganti, L. N. P.; Cortese, Leonardo; Oyewumi, L. Kola; Cernovsky, Zack Z.; Zirul, Sandra; Awad, A. George

doi:10.1016/s0920-9964(99)00154-1

Cited by 223 publications

(138 citation statements)

References 38 publications

Supporting

Mentioning

126

Contrasting

Unclassified

Order By: Relevance

“…Polypharmacy of antipsychotics and concurrent use of anticholinergics, anxiolytics, or hypnotics were more frequently found in Tokyo. Past studies [4,5,18,19] indicated that patients' subjective responses are generally more favorable to atypical antipsychotics than to typical antipsychotics, but in Tokyo, the advantage of atypical antipsychotics would be compromised by frequent concomitant use of typical antipsychotics. The differences between the two countries align with past reports d Patients' subjective evaluation using a 4-point Likert scale from 1(not bothered at all) to 4 (bothered very much) *P \ 0.05, **P \ 0.01, ***P \ 0.001 Table 4 Stepwise multiple regression analysis of DAI- comparing prescription practices for inpatients [1,2].…”

Section: Discussionmentioning

confidence: 99%

Attitudes toward taking medication among outpatients with schizophrenia: cross-national comparison between Tokyo and Beijing

Kuroda

Sun

Lin

et al. 2008

Environ Health Prev Med

View full text Add to dashboard Cite

Objectives The aim of this study was to compare attitudes toward medication and associated factors for patients with schizophrenia in Japan and China. Methods Age-group matched samples were drawn from outpatients in Tokyo (N = 76) and Beijing (N = 76) according to the same inclusion/exclusion criteria. Psychotropic prescription and attitudes toward medication were measured using Drug Attitude Inventory-30 (DAI-30) and an original questionnaire regarding beliefs about psychiatric medication. Stepwise regression analysis of the DAI-30 data was performed for each group. Results Japanese subjects were prescribed significantly larger amounts of antipsychotics. Polypharmacy of antipsychotics and concurrent use of anticholinergics, anxiolytics, or hypnotics were more frequently found among subjects in Tokyo than among those in Beijing. However, subjects in Tokyo and Beijing had similar subjective responses to medication, subjective evaluation of sideeffects, and complaints about overuse of psychotropics. Subjects in Tokyo complained less about physician's overreliance on medication and were less concerned about medication cost than those in Beijing. In Tokyo, longer duration of illness and lower subjective distress caused by side effects predicted a more positive subjective response, while female gender, younger age, and lower Brief Psychiatric Rating Scale score were independently correlated with a better subjective response in Beijing. Conclusions Subjective acceptance of multiple medications is greater for patients in Japan than those in China. Determinants of subjective response to medication varied between Japan and China.

show abstract

Section: Discussionmentioning

confidence: 99%

Attitudes toward taking medication among outpatients with schizophrenia: cross-national comparison between Tokyo and Beijing

Kuroda

Sun

Lin

et al. 2008

Environ Health Prev Med

View full text Add to dashboard Cite

show abstract

“…Improved tolerability with the newer drugs has been widely reported in terms of sideeffects and subjective experience. [21][22][23] While it is reasonable to speculate that better subjective tolerability might translate into better compliance in the long term, as yet there are no convincing data to support such a view.…”

Section: Therapeutic Efficacymentioning

confidence: 99%

Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment

Lewis

Davies²,

Jones³

et al. 2006

Health Technol Assess

135

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. Declared competing interests of authors: SW Lewis received support for travel to meetings and honoraria for consultancies from AstraZeneca, Lilly, BristolMyersSquibb, Pfizer, Janssen, Wyeth, Lundbeck, GlaxoSmithKline and Novartis. L Davies received funding for preparing papers and attendance at meetings from Janssen, Hoechst Marion Roussel, Pfizer, AstraZeneca and Lundbeck, and project funding from Novartis. PB Jones received travel support to academic meetings from companies manufacturing drugs used in this study, and unrestricted use of honoraria and consultancy fees for some work for academic use in his department and elsewhere. TRE Barnes received travel support to academic meetings and honoraria for consultancy from companies manufacturing drugs used in this study, plus the award of a grant from Sanofi-Synthelabo for an investigator-initiated study. RM Murray received honoraria and advisory fees from pharmaceutical companies (paid into departmental research funds). R Kerwin received honoraria and advisory fees from pharmaceutical companies and received research grants for non-clinical research from Novartis. D Taylor received honoraria for a lecture and consultancy from manufacturers of atypical antipsy...

show abstract

“…DAI is an established rating scale for quantifying subjective tolerability of antipsychotic drugs, and the cumulative score on the scale ranges between ϩ 10 and Ϫ 10 (Awad 1993). The shorter version of the scale was administered on earlier occasions while the subjects were receiving antipsychotic drugs (Voruganti et al 2000). For the purpose of this study, subjects who received a negative score (0 to Ϫ 10) were designated as "dysphoric" responders, and those who received a positive score (0 to ϩ 10) were considered as "non-dysphoric" responders.…”

Section: Subjectsmentioning

confidence: 99%

Subjective Effects of AMPT-induced Dopamine Depletion in Schizophrenia Correlation between Dysphoric Responses and Striatal D2 Binding Ratios on SPECT Imaging

Voruganti

Slomka

Zabel

et al. 2001

Neuropsychopharmacology

Self Cite

View full text Add to dashboard Cite

Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life

Cited by 223 publications

References 38 publications

Attitudes toward taking medication among outpatients with schizophrenia: cross-national comparison between Tokyo and Beijing

Attitudes toward taking medication among outpatients with schizophrenia: cross-national comparison between Tokyo and Beijing

Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment

Subjective Effects of AMPT-induced Dopamine Depletion in Schizophrenia Correlation between Dysphoric Responses and Striatal D2 Binding Ratios on SPECT Imaging

Contact Info

Product

Resources

About